3,4-Dihydroxybenzaldehyde
Common Name: |
3,4-Dihydroxybenzaldehyde |
IUPAC Name: |
3,4-dihydroxybenzaldehyde |
Molecular Formula: |
C7H6O3 |
SMILES: |
C1=CC(=C(C=C1C=O)O)O |
Inchi: |
1S/C7H6O3/c8-4-5-1-2-6(9)7(10)3-5/h1-4,9-10H |
Inchi Key: |
IBGBGRVKPALMCQ-UHFFFAOYSA-N |
Cas No: |
139-85-5 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
3 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
138.12 |
Mass (g/mol) |
138.032 |
Molar Refractivity |
35.88 |
Net Charge |
|
HBD |
2 |
HBA |
3 |
Rt Bonds |
1 |
Rings |
1 |
TPSA |
57.53 |
Hetero Atoms |
3 |
Heavy Atoms |
10 |
Aromatic Heavy Atoms |
6 |
Melting Point (°C) |
154.00 to 155.00 |
Boiling Point (°C@760.00mm Hg) |
323 |
Vapor Pressure (mmHg@25.00 °C) |
0.00011 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.00 |
LogP |
0.91 |
iLOGP |
0.79 |
XLOGP3 |
1.09 |
WLOGP |
0.91 |
MLOGP |
0.18 |
ESOL Log S |
-1.76 |
ESOL Solubility (mg/ml) |
2.39 |
ESOL Solubility (mol/l) |
0.017 |
ESOL Class: esol_class |
Very soluble |
Ali Log S |
-1.89 |
Ali Solubility (mg/ml) |
1.78 |
Ali Solubility (mol/l) |
0.01 |
Ali Class |
Very soluble |
Silicos-IT LogSw |
-1.17 |
Silicos-IT Solubility (mg/ml) |
9.4 |
Silicos-IT Solubility (mol/l) |
0.07 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-6.37 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.679 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
1 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.69 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Warning |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |